Summit Therapeutics Inc.
NASDAQ:SMMT · NASDAQ Global Market
+$0.19 today
Vol 7.26M · Avg 4.77M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-220.8%
avg -42.2%
ROIC
-216.3%
avg -90.6%
ROA
-193.6%
avg -75.6%
Analysis
ROA is currently the strongest return metric at -193.6% versus its period average of -75.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mahkam Zanganeh | Co-CEO, President & Director | $1.03M | — | 56 | $573.88M | 74.01% |
Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director | $1.03M | — | 48 | $3.12M | 0.40% |
Robert W. Duggan | Co-CEO & Executive Chairman | $172,376.00 | — | 81 | $573.88M | 74.01% |
Bilal Piperdi | Chief Medical Officer | — | — | — | — | — |
Howard Jack West | Vice President of Clinical Development | — | — | — | — | — |
Nathan LiaBraaten | Senior Director of Investor Relations | — | — | — | — | — |
Laura Q. Chow | Senior Vice President of Clinical Development | — | — | — | — | — |
Urte Gayko | Chief Regulatory, Quality & Pharmacovigilance Officer | — | — | 55 | $400,000.00 | 0.05% |
Bhaskar Anand | Chief Accounting Officer | — | — | 49 | $30,000.00 | <0.01% |
Dave Gancarz | Chief Business & Strategy Officer | — | — | — | — | — |
Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | — | — | 75 | — | — |
Allen S. Yang | Head of R&D Strategy | — | — | 58 | — | — |
Wang Clow Fong | Chief Biometrics Officer | — | — | 68 | $91,096.00 | 0.01% |
Robert LaCaze | Chief Commercial Officer | — | — | — | $573.88M | 74.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
13
$126.59M
Sells
0
$0.00
Net Sentiment
+$126.59M
Net buying
Most Active
DUGGAN ROBERT W
5 transactions
1–10 of 13
Analysis
Insiders reported 13 buys worth $126.59M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $126.59M. DUGGAN ROBERT W was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -12.2% | +70.8% (15yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -12.2% over three years. Forward estimates point to Revenue at +70.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$33.54B
Moderna, Inc.
NASDAQ:MRNA
$24.52B
Royalty Pharma plc
NASDAQ:RPRX
$23.10B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.44B
Exact Sciences Corporation
EXAS
$20.03B
Ascendis Pharma A/S
NASDAQ:ASND
$14.36B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.20B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.28B
Universal Health Services, Inc.
NYSE:UHS
$8.84B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$213.48M
Who manages SMMT?
Summit Therapeutics Inc. (SMMT) lists 14 active executives. The top listed executive is Mahkam Zanganeh, Co-CEO, President & Director.
Are SMMT insiders buying or selling?
Recent insider activity shows net buying of $1.52B.
Explore More
Continue the stock analysis
Jump to another research area for this company.